CLINICAL_TRIALS
trial_result
· 2026-04-20
Clinical Trial Update: Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma [Phase 2]
Summary
A Phase 2 study evaluating glofitamab with pirtobrutinib for relapsed or refractory mantle cell lymphoma is currently recruiting.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University of California, San Francisco | Conditions: Mantle Cell Lymphoma | Phase 2 | Status: RECRUITING